The company is not selling any securities under this prospectus and will not receive any of the proceeds from the sale of common shares by the selling securityholders.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PBM:
- Psyence Group Sells Stake to Psyence Biomedical
- Psyence Biomedical to acquire 11.13% stake in PsyLabs
- Psyence CEO says positioned ‘to be a leader’ in psychedelic-based therapeutics
- Psyence Biomedical Faces Nasdaq Delisting Risk
- Psyence Biomedical intiates first trial site in Australia for Phase IIb study